Telo Genomics (TSX.V: TELO) (OTCQB: TDSGF),a biotech company developing the industry’s leading telomere technology platform with diagnostic and prognostic applications measuring genomic instability in oncology, has received accreditation for its Toronto-based laboratory at the MaRS Center from the Accreditation Committee of the College of American Pathologists (“CAP”). The accreditation followed more than a year of preparation and an on-site inspection by the CAP Accreditation Programs. CAP is the world’s largest organization of board-certified pathologists and leading provider of laboratory accreditation and proficiency testing programs, and its accreditation recognizes rigorous and robust standards.
“The CAP accreditation highlights Telo Genomics’ commitment and focus in pursuit of the commercialization of its TeloView diagnostic and prognostic technologies, and the company’s preparedness to capitalize on ongoing partnership discussions with diagnostic and pharma leaders in the field,” said Tele Genomics president and CTO Sherif Louis in the press release. “We thank Dr. Hans Knecht, head of hematology at McGill University and the Jewish General Hospital and Telo’s medical lab director, for his valuable guidance leading us to achieve such an important milestone.”
To view the full press release, visit https://ibn.fm/jZiT4
About Telo Genomics Corp.
Telo Genomics is a biotech company pioneering the most comprehensive telomere platform in the industry with powerful applications and prognostic solutions. These include liquid biopsies and related technologies in oncology and neurological diseases. Liquid biopsy is a rapidly growing field of significant interest to the medical community for being less invasive and more easily replicated than traditional diagnostic approaches. By combining the company’s considerable expertise in quantitative analysis of 3D telomeres with molecular biology and artificial intelligence to recognize disease-associated genetic instability, TELO is developing simple and accurate products that improve day-to-day care for patients by serving the needs of pathologists, clinicians, academic researchers and drug developers. The benefits of TeloGenomics’ proprietary technology have been substantiated in more than 160 peer-reviewed publications and in 30-plus clinical studies involving more than 3,000 patients with multiple cancers and Alzheimer’s disease. The company’s lead application, TELO-MM, is being developed to provide important, actionable information to medical professionals in the treatment of multiple myeloma, a deadly form of blood cancer. For more information about the company, please visit www.TeloDX.com.
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]
InvestorWire is powered by IBN